JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M201208200 on August 9, 2002

J. Biol. Chem., Vol. 277, Issue 52, 50237-50244, December 27, 2002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/52/50237    most recent
M201208200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, J.
Right arrow Articles by Kurland, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, J.
Right arrow Articles by Kurland, I. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Peroxisome Proliferator-activated Receptor alpha  (PPARalpha ) Influences Substrate Utilization for Hepatic Glucose Production*

Jun XuDagger §, Gary XiaoDagger §, Chuck TrujilloDagger §, Vicky ChangDagger §, Lilia BlancoDagger §, Sean B. Joseph||, Sara Bassilian**, Mohammed F. Saad§, Peter Tontonoz||Dagger Dagger §§, W. N. Paul Lee**, and Irwin J. KurlandDagger §Dagger Dagger ¶¶

From the § Department of Medicine, the Dagger  Laboratory of Metabolomics, the  Department of Biological Chemistry, the || Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, Dagger Dagger  Molecular Biology Institute, UCLA, Los Angeles, California 90095, and the ** Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, California 90502

The hypoglycemia seen in the fasting PPARalpha null mouse is thought to be due to impaired liver fatty acid beta -oxidation. The etiology of hypoglycemia in the PPARalpha null mouse was determined via stable isotope studies. Glucose, lactate, and glycerol flux was assessed in the fasted and fed states in 4-month-old PPARalpha null mice and in C57BL/6 WT maintained on standard chow using a new protocol for flux assessment in the fasted and fed states. Hepatic glucose production (HGP) and glucose carbon recycling were estimated using [U-13C6]glucose, and HGP, lactate, and glycerol turnover was estimated utilizing either [U-13C3]lactate or [2-13C]glycerol infused subcutaneously via Alza miniosmotic pumps. At the end of a 17-h fast, HGP was higher in the PPARalpha null mice than in WT by 37% (p < 0.01). However, recycling of glucose carbon from lactate back to glucose was lower in the PPARalpha null than in WT (39% versus 51%, p < 0.02). The lack of conversion of lactate to glucose was confirmed using an [U-13C3]lactate infusion. In the fasted state, HGP from lactate and lactate production were decreased by 65 and 55%, respectively (p < 0.05) in PPARalpha null mice. In contrast, when [2-13C]glycerol was infused, glycerol production and HGP from glycerol increased by 80 and 250%, respectively (p < 0.01), in the fasted state of PPARalpha null mice. The increased HGP from glycerol was not suppressed in the fed state. While little change was evident for phosphoenolpyruvate carboxykinase (PEPCK) expression, pyruvate kinase expression was decreased 16-fold in fasted PPARalpha null mice as compared with the wild-type control. The fasted and fed insulin levels were comparable, but blood glucose levels were lower in the PPARalpha null mice than in controls. In conclusion, PPARalpha receptor function creates a setpoint for a metabolic network that regulates the rate and route of HGP in the fasted and fed states, in part, by controlling the flux of glycerol and lactate between the triose-phosphate and pyruvate/lactate pools.

* This work was supported by a grant from the American Diabetes Association (to I. J. K.) and Grants DK56090-A1 (to W. N. P. L.) and HL66088 (to P. T.). The GC/MS Facility is supported by United States Public Health Service Grant P01-CA42710 to the UCLA Clinical Nutrition Research Unit, Stable Isotope Core and Grant M01-RR00425 to the General Clinical Research Center.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§§ Assistant investigator of the Howard Hughes Medical Institute at the University of California, Los Angeles, CA 90095.

¶¶ To whom correspondence should be addressed. Tel.: 818-634-6953; Fax: 310-825-8534; E-mail address: irwinjk@earthlink.net.

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
M. H. Liu, J. Li, P. Shen, B. Husna, E. S. Tai, and E. L. Yong
A Natural Polymorphism in Peroxisome Proliferator-Activated Receptor-{alpha} Hinge Region Attenuates Transcription due to Defective Release of Nuclear Receptor Corepressor from Chromatin
Mol. Endocrinol., May 1, 2008; 22(5): 1078 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Neschen, K. Morino, J. Dong, Y. Wang-Fischer, G. W. Cline, A. J. Romanelli, J. C. Rossbacher, I. K. Moore, W. Regittnig, D. S. Munoz, et al.
n-3 Fatty Acids Preserve Insulin Sensitivity In Vivo in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner
Diabetes, April 1, 2007; 56(4): 1034 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Xu, L. Gowen, C. Raphalides, K. K. Hoyer, J. G. Weinger, M. Renard, J. J. Troke, B. Vaitheesyaran, W.N. P. Lee, M. F. Saad, et al.
Decreased Hepatic Futile Cycling Compensates for Increased Glucose Disposal in the Pten Heterodeficient Mouse
Diabetes, December 1, 2006; 55(12): 3372 - 3380.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Xu, W.N. P. Lee, J. Phan, M. F. Saad, K. Reue, and I. J. Kurland
Lipin Deficiency Impairs Diurnal Metabolic Fuel Switching
Diabetes, December 1, 2006; 55(12): 3429 - 3438.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
H. J. Atherton, N. J. Bailey, W. Zhang, J. Taylor, H. Major, J. Shockcor, K. Clarke, and J. L. Griffin
A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-{alpha} null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome
Physiol Genomics, October 11, 2006; 27(2): 178 - 186.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Knauf, J. Rieusset, M. Foretz, P. D. Cani, M. Uldry, M. Hosokawa, E. Martinez, M. Bringart, A. Waget, S. Kersten, et al.
Peroxisome Proliferator-Activated Receptor-{alpha}-Null Mice Have Increased White Adipose Tissue Glucose Utilization, GLUT4, and Fat Mass: Role in Liver and Brain
Endocrinology, September 1, 2006; 147(9): 4067 - 4078.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
B. Desvergne, L. Michalik, and W. Wahli
Transcriptional Regulation of Metabolism
Physiol Rev, April 1, 2006; 86(2): 465 - 514.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. C. Burgess, F. M. H. Jeffrey, C. Storey, A. Milde, N. Hausler, M. E. Merritt, H. Mulder, C. Holm, A. D. Sherry, and C. R. Malloy
Effect of murine strain on metabolic pathways of glucose production after brief or prolonged fasting
Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E53 - E61.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Genolet, S. Kersten, O. Braissant, S. Mandard, N. S. Tan, P. Bucher, B. Desvergne, L. Michalik, and W. Wahli
Promoter Rearrangements Cause Species-specific Hepatic Regulation of the Glyoxylate Reductase/Hydroxypyruvate Reductase Gene by the Peroxisome Proliferator-activated Receptor {alpha}
J. Biol. Chem., June 24, 2005; 280(25): 24143 - 24152.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Gremlich, C. Nolan, R. Roduit, R. Burcelin, M.-L. Peyot, V. Delghingaro-Augusto, B. Desvergne, L. Michalik, M. Prentki, and W. Wahli
Pancreatic Islet Adaptation to Fasting Is Dependent on Peroxisome Proliferator-Activated Receptor {alpha} Transcriptional Up-Regulation of Fatty Acid Oxidation
Endocrinology, January 1, 2005; 146(1): 375 - 382.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Heron-Milhavet, M. Haluzik, S. Yakar, O. Gavrilova, S. Pack, W. C. Jou, A. Ibrahimi, H. Kim, D. Hunt, D. Yau, et al.
Muscle-Specific Overexpression of CD36 Reverses the Insulin Resistance and Diabetes of MKR Mice
Endocrinology, October 1, 2004; 145(10): 4667 - 4676.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Tzameli, H. Fang, M. Ollero, H. Shi, J. K. Hamm, P. Kievit, A. N. Hollenberg, and J. S. Flier
Regulated Production of a Peroxisome Proliferator-activated Receptor-{gamma} Ligand during an Early Phase of Adipocyte Differentiation in 3T3-L1 Adipocytes
J. Biol. Chem., August 20, 2004; 279(34): 36093 - 36102.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. Desvergne, L. Michalik, and W. Wahli
Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road
Mol. Endocrinol., June 1, 2004; 18(6): 1321 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
P. Maruvada and S. Srivastava
Biomarkers for Cancer Diagnosis: Implications for Nutritional Research
J. Nutr., June 1, 2004; 134(6): 1640S - 1645S.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. H. J. Bandsma, T. H. van Dijk, A. t. Harmsel, T. Kok, D.-J. Reijngoud, B. Staels, and F. Kuipers
Hepatic de Novo Synthesis of Glucose 6-Phosphate Is Not Affected in Peroxisome Proliferator-activated Receptor {alpha}-Deficient Mice but Is Preferentially Directed toward Hepatic Glycogen Stores after a Short Term Fast
J. Biol. Chem., March 5, 2004; 279(10): 8930 - 8937.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Xu, V. Chang, S. B. Joseph, C. Trujillo, S. Bassilian, M. F. Saad, W. N. P. Lee, and I. J. Kurland
Peroxisomal Proliferator-Activated Receptor {alpha} Deficiency Diminishes Insulin-Responsiveness of Gluconeogenic/Glycolytic/Pentose Gene Expression and Substrate Cycle Flux
Endocrinology, March 1, 2004; 145(3): 1087 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
S. Li, P. Wu, P. Yarlagadda, N. M. Vadjunec, A. D. Proia, R. A. Harris, and D. Portilla
PPAR{alpha} ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity
Am J Physiol Renal Physiol, March 1, 2004; 286(3): F572 - F580.
[Abstract] [Full Text]

Home page
 Physiol. GenomicsHome page
F. Yadetie, A. Laegreid, I. Bakke, W. Kusnierczyk, J. Komorowski, H. L. Waldum, and A. K. Sandvik
Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-{alpha} agonist ciprofibrate
Physiol Genomics, September 29, 2003; 15(1): 9 - 19.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.